Idiopathic alveolar proteinosis. The common presentation of a rare disease
Proteinosis alveolar idiopática. La presentación común de una rara enfermedad
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Pulmonary alveolar proteinosis (PAP) is a rare condition of unknown etiology that is characterized by an abnormal accumulation of lipoproteinaceus material within the alveoli. Today, three types of presentations have been identified (congenital, secondary and acquired) which have, as a common denominator, an extensive lung involvement. Primary alterations include a decrease in the clearance of surfactant or an increase in the production thereof, alterations involving genetic defects that alter the proteins that comprise the surfactant or the receptor of GM - CSF. The acquired presentation is characterized by the presence of anti – GM-CSF antibodies, thus highlighting the role of this substance in surfactant homeostasis. On this occasion, we present the case of a young female patient with lower respiratory symptoms, in whom, the low correlation between clinical appearance and extensive pulmonary parenchymal compromise is a remarkable feature.
Article visits 465 | PDF visits 547
Downloads
- Shah PL, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax. 2000;55:67-77.
- Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med. 1958;258:1123-42.
- Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215-35.
- Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527-39.
- Dranoff G, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264:713-6.
- deMello DE, Lin Z. Pulmonary alveolar proteinosis: a review. Pediatr Pathol Mol Med. 2001;20:413-32.
- Garcia Rio F, et al. Six cases of pulmonary alveolar proteinosis: presentation of unusual associations. Monaldi Arch Chest Dis. 1995;50:12-5.
- Bonfield TL, et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol. 2002;27:481-6.
- Miyatake S, et al. Structure of the chromosomal gene for granulocytemacrophage colony stimulating factor: comparison of the mouse and human genes. EMBOJ. 1985;4:2561-8.
- Goldstein LS, et al. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest. 1998;114:1357-62.
- Prakash UB, et al. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc. 1987;62:499-518.
- Lee KN, et al. Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest, 1997;111:989-95.
- Fraimow W, Cathcart RT, Taylor RC. Physiologic and clinical aspects of pulmonary alveolar proteinosis. Ann Intern Med. 1960;52:1177-94.
- Lin FC, et al. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax. 2006;61:528-34.
- Ramirez J, Schultz RB, Dutton RE. Pulmonary alveolar proteinosis: a new technique and rationale for treatment. Arch Intern Med. 1963;112:419-31.
- Seymour JF, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001;163:524-31.
- Hamvas A, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr. 1997;130:231-9.
- Tazawa R, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2005; 171:1142-9.